Claim OwnershipGRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Subscribed: 2Played: 84
Subscribe
© Copyright cancerGRACE
Description
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
202 Episodes
Reverse
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC
Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.
Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.
Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Joshua Reuss examines data on neoadjuvant targeted therapy.
Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC.
Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).
Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.
Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.
Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.
Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.
Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.
Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease.
Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC.
Comments
Download from Google Play
Download from App Store
United States